NASDAQ · Biotechnology · USD

Vicore Pharma Holding AB (publ) (VCRE) Stock Analysis

Vicore Pharma Holding AB (publ) (VCRE) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 22, 2026

VCRE

$10.32

+$1.04 (+11.21%)

Oct 22, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare VCRE with… →

VCRE Key Statistics

As of Oct 22, 2026

Trading

Open: $9.16
Previous Close: $9.28
Day's Range: 8.90–11.47
52-Week Range: 7.88–17.80
Volume: 103.33K
Beta: 0.09

Valuation

Market Cap: $290.66M
P/E Ratio: unprofitable
EPS (ttm): −2.04

Financials (FY)

Revenue (FY): $3.82M−96.51%
Net Income (FY): −$477.47M
Shares Outstanding: 28.16M

Dividend and dates

Avg Volume: 18.18K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

Vicore Pharma Holding AB (publ) (VCRE) has a market capitalization of $290.66M.

In fiscal 2025, VCRE reported revenue of $3.82M.

VCRE Revenue and Earnings by Fiscal Year

FY ends December

RevenueNet income

2022202320242025

Fiscal year	Revenue	Net income	Net margin
2025	$3.82M	−$477.47M	−12,509.1%
2024	$109.35M	−$168.63M	−154.2%
2023	$0.00	−$310.94M	—
2022	$0.00	−$288.42M	—

Fiscal year	Revenue	Gross profit	Operating income	Net income	Net margin
2025	$3.82M	$3.82M	−$454.45M	−$477.47M	−12,509.1%
2024	$109.35M	$109.35M	−$190.36M	−$168.63M	−154.2%
2023	$0.00	$0.00	−$320.89M	−$310.94M	—
2022	$0.00	$0.00	−$287.49M	−$288.42M	—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values Vicore Pharma Holding AB (publ) (VCRE) at $290.66M. It is classified in the Biotechnology industry, within the Healthcare sector. The company reports 46 employees.

Over the past 52 weeks the price has ranged from $7.88 to $17.80. VCRE last closed at $10.32 on October 22, 2026. That is +$1.04 (+11.21%) against the previous close. The latest close sits 30.96% above that 52-week low.

Financial Health

In fiscal 2025, Vicore Pharma Holding AB (publ) reported revenue of $3.82M. That is −96.51% against the prior fiscal year, when revenue was $109.35M. The same year closed with a net loss of $477.47M. Trailing earnings per share are −2.04.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $3.82M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published.

Beta against the wider market is reported at 0.09.

Growth & Income

No dividend is on file for VCRE.

2026 is still running; the total return is −36.49% year to date.

Peer Comparison

Vicore Pharma Holding AB (publ) (VCRE) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company	Ticker	Market Cap	P/E Ratio
Vicore Pharma Holding AB (publ)	VCRE	$290.66M	—
Vertex Pharmaceuticals Incorporated	VRTX	$135.64B	31.0
Regeneron Pharmaceuticals, Inc.	REGN	$84.33B	20.3
Moderna, Inc.	MRNA	$80.90B	—

The Biotechnology industry average P/E ratio is 16.6x. Vicore Pharma Holding AB (publ) has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 22, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$135.64B

REGN

Regeneron Pharmaceuticals, Inc.

$84.33B

MRNA

Moderna, Inc.

$80.90B

ARGX

argenx SE

$55.07B

ONC

BeOne Medicines AG

$43.49B

RVMD

Revolution Medicines, Inc.

$40.23B

View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.17T

JNJ

Johnson & Johnson

$644.91B

ABBV

AbbVie Inc.

$503.96B

UNH

UnitedHealth Group Incorporated

$381.46B

MRK

Merck & Co., Inc.

$363.27B

View all Healthcare stocks →

About Vicore Pharma Holding AB (publ)

Vicore Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops therapies for the treatment of respiratory diseases in Sweden. The company develops Buloxibutid (C21), an orally available small molecule angiotensin II type 2 receptor agonist (ATRAG) that is in Phase II clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF), as well as in Phase I clinical trial for treating pulmonary hypertension. It also developing Almee, an investigational medical device in clinical development that has completed Phase III clinical stage to address the psychological impact of living with pulmonary fibrosis. It has a cooperation and development agreement with Emeriti Bio AB and HaLaCore Pharma AB to develop new follow-on molecules based on C21 and other drug substances targeting the AT2 receptor, as well as a collaboration and development agreement with Alex Therapeutics AB to develop a digital app in interstitial lung diseases, such as IPF. The company was formerly known as Mintage Scientific AB. Vicore Pharma Holding AB (publ) was founded in 2000 and is headquartered in Stockholm, Sweden.

Visit website →